^
Association details:
| Biomarker: | MSH2 negative + MSH6 negative |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series
Published date:
07/01/2020
Excerpt:
A man aged 81 years with a history of prostate cancer...with loss of MSH2 and MSH6 expression in both tumors...the patient was started on neoadjuvant pembrolizumab, 200 mg every 3 weeks....restaging MRI showed tumor regression of the low rectal lesion from 5 to 2.5 cm...
DOI:
10.6004/jnccn.2020.7558
